Adenosine deaminase inhibition prevents Clostridium difficile toxin A-induced enteritis in mice

Infection and Immunity

Volumn 79, Issue 2, 2011, Pages 653-662

  De Araújo Junqueira, Ana Flávia Torquato ^a   Martins Dias, Adriana Abalen ^b   Lima Vale, Mariana ^a   Turco Spilborghs, Graziela Machado Gruner ^b   Siqueira Bossa, Aline ^b   Bezerra Lima, Bruno ^a   Fiorini Carvalho, Alex ^b   Littleton Guerrant, Richard ^c   Albuquerque Ribeiro, Ronaldo ^a   Anne Brito, Gerly ^a  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b A C CAMARGO CANCER CENTER   (Brazil)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 (2 HYDROXY 3 NONYL)ADENINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE DEAMINASE; CLOSTRIDIUM DIFFICILE TOXIN A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; MYELOPEROXIDASE; PENTRAXIN 3; PHOSPHATE BUFFERED SALINE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DRUG MECHANISM; ENTERITIS; ENZYME ASSAY; ENZYME INHIBITION; GENE EXPRESSION; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; ILEUM; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE INJURY;

ADENINE; ADENOSINE DEAMINASE; ADENOSINE DEAMINASE INHIBITORS; ANIMALS; BACTERIAL TOXINS; BENZYL COMPOUNDS; C-REACTIVE PROTEIN; CLOSTRIDIUM DIFFICILE; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENTERITIS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; ENTEROTOXINS; GENE EXPRESSION REGULATION; ILEUM; MICE; NERVE TISSUE PROTEINS; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II;

EID: 79251490670     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01159-10     Document Type: Article

References (57)

1. Barankiewicz, J., et al. 1997. Regulation of adenosine concentration and cytoprotective effects of novel reversible adenosine deaminase inhibitors. J. Pharmacol. Exp. Ther. 283:1230-1238.
2. Barreto, A. R., et al. 2008. Fucoidin prevents Clostridium difficile toxin-Ainduced ileal enteritis in mice. Dig. Dis. Sci. 53:990-996.
3. Bartlett, J. G. 2002. Clinical practice. Antibiotic-associated diarrhea. N. Engl. J. Med. 346:334-339.
4. Blossom, D. B., and L. C. McDonald. 2007. The challenges posed by reemerging Clostridium difficile infection. Clin. Infect. Dis. 45:222-227.
5. Bours, M. J., E. L. Swennen, V. F. Di, B. N. Cronstein, and P. C. Dagnelie. 2006. Adenosine 5-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol. Ther. 112:358-404.
6. Bradley, P. P., R. D. Christensen, and G. Rothstein. 1982. Cellular and extracellular myeloperoxidase in pyogenic inflammation. Blood 60:618-622.
7. Brito, G. A., et al. 2005. Clostridium difficile toxin A induces intestinal epithelial cell apoptosis and damage: role of Gln and Ala-Gln in toxin A effects. Dig. Dis. Sci. 50:1271-1278.
8. Brito, G. A., et al. 2002. Mechanism of Clostridium difficile toxin A-induced apoptosis in T84 cells. J. Infect. Dis. 186:1438-1447.
9. Brito, G. A., et al. 2002. Clostridium difficile toxin A alters in vitro-adherent neutrophil morphology and function. J. Infect. Dis. 185:1297-1306.
10. Cavalcante, I. C., et al. 2006. Effect of novel A2A adenosine receptor agonist ATL313 on Clostridium difficile toxin A-induced murine ileal enteritis. Infect. Immun. 74:2606-2612.
11. Cronstein, B. N. 1994. Adenosine, an endogenous anti-inflammatory agent. J. Appl. Physiol. 76:5-13.
12. Dias, A. A., et al. 2001. TSG-14 transgenic mice have improved survival to endotoxemia and to CLP-induced sepsis. J. Leukoc. Biol. 69:928-936.
13. Diniz, S. N., et al. 2004. PTX3 function as an opsonin for the dectin-1-dependent internalization of zymosan by macrophages. J. Leukoc. Biol. 75:649-656.
14. Doni, A., et al. 2003. Production of the soluble pattern recognition receptor PTX3 by myeloid, but not plasmacytoid, dendritic cells. Eur. J. Immunol. 33:2886-2893.
15. Eigler, A., et al. 2000. Suppression of TNF-alpha production in human mononuclear cells by an adenosine kinase inhibitor. J. Leukoc. Biol. 68:97-103.
16. Flegel, W. A., et al. 1991. Cytokine response by human monocytes to Clostridium difficile toxin A and toxin B. Infect. Immun. 59:3659-3666.
17. Fredholm, B. B., A. P. Ijzerman, K. A. Jacobson, K. N. Klotz, and J. Linden. 2001. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 53:527-552.
18. Garlanda, C., et al. 2002. Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature 420:182-186.
19. Giusti, G. 1974. Adenosine deaminase, p. 1092-1099. In H. U. Bergmeyer (ed.), Methods of enzymatic analysis., vol. 2. Academic Press, Inc., New York, NY.
20. Glover, D. K., et al. 2005. Reduction of infarct size and postischemic inflammation from ATL-146e, a highly selective adenosine A2A receptor agonist, in reperfused canine myocardium. Am. J. Physiol. Heart Circ. Physiol. 288:H1851-H1858.
21. Haskó, G., and B. N. Cronstein. 2004. Adenosine: an endogenous regulator of innate immunity. Trends Immunol. 25:33-39.
22. Hausding, M., et al. 2000. Inhibition of small G proteins of the rho family by statins or clostridium difficile toxin B enhances cytokine-mediated induction of NO synthase II. Br. J. Pharmacol. 131:553-561.
23. Hsu, S. M., L. Raine, and H. Fanger. 1981. The use of antiavidin antibody and avidin-biotin-peroxidase complex in immunoperoxidase technics. Am. J. Clin. Pathol. 75:816-821.
24. Hua, X., et al. 2007. Enhanced mast cell activation in mice deficient in the A2b adenosine receptor. J. Exp. Med. 204:117-128.
25. Humphrey, C. D., C. W. Condon, J. R. Cantey, and F. E. Pittman. 1979. Partial purification of a toxin found in hamsters with antibiotic-associated colitis. Reversible binding of the toxin by cholestyramine. Gastroenterology 76:468-476.
26. Jeremy, J. Y., A. P. Yim, S. Wan, and G. D. Angelini. 2002. Oxidative stress, nitric oxide, and vascular disease. J. Card. Surg. 17:324-327.
27. Kelly, C. P., et al. 1994. Neutrophil recruitment in Clostridium difficile toxin A enteritis in the rabbit. J. Clin. Investig. 93:1257-1265.
28. Kelly, C. P., and J. T. LaMont. 2008. Clostridium difficile - more difficult than ever. N. Engl. J. Med. 359:1932-1940.
29. Kirkwood, K. S., et al. 2001. Deletion of neutral endopeptidase exacerbates intestinal inflammation induced by Clostridium difficile toxin A. Am. J. Physiol. Gastrointest. Liver Physiol. 281:G544-G551.
30. Kreckler, L. M., T. C. Wan, Z. D. Ge, and J. A. Auchampach. 2006. Adenosine inhibits tumor necrosis factor-alpha release from mouse peritoneal macrophages via A2A and A2B but not the A3 adenosine receptor. J. Pharmacol. Exp. Ther. 317:172-180.
31. Kyne, L., M. Warny, A. Qamar, and C. P. Kelly. 2000. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N. Engl. J. Med. 342:390-397.
32. Lee, T. H., G. W. Lee, E. B. Ziff, and J. Vilcek. 1990. Isolation and characterization of eight tumor necrosis factor-induced gene sequences from human fibroblasts. Mol. Cell. Biol. 10:1982-1988.
33. Leitão, R. F., et al. 2007. Role of nitric oxide on pathogenesis of 5-fluorouracil induced experimental oral mucositis in hamster. Cancer Chemother. Pharmacol. 59:603-612.
34. Lyerly, D. M., H. C. Krivan, and T. D. Wilkins. 1988. Clostridium difficile: its disease and toxins. Clin. Microbiol. Rev. 1:1-18.
35. Lyras, D., et al. 2009. Toxin B is essential for virulence of Clostridium difficile. Nature 458:1176-1179.
36. Martin, L., S. C. Pingle, D. M. Hallam, L. P. Rybak, and V. Ramkumar. 2006. Activation of the adenosine A3 receptor in RAW 264.7 cells inhibits lipopolysaccharide-stimulated tumor necrosis factor-alpha release by reducing calcium-dependent activation of nuclear factor-kappaB and extracellular signal-regulated kinase 1/2. J. Pharmacol. Exp. Ther. 316:71-78.
37. Melo Filho, A. A., et al. 1997. Role of tumor necrosis factor and nitric oxide in the cytotoxic effects of Clostridium difficile toxin A and toxin B on macrophages. Toxicon 35:743-752.
38. Muniyappa, R., R. Xu, J. L. Ram, and J. R. Sowers. 2000. Inhibition of Rho protein stimulates iNOS expression in rat vascular smooth muscle cells. Am. J. Physiol. Heart Circ. Physiol. 278:H1762-H1768.
39. Pfaffl, M. W. 2001. A new mathematical model for relative quantification in real-time PCR. Nucleic Acids Res. 29:e45.
40. Pothoulakis, C., I. Castagliuolo, and J. T. LaMont. 1998. Nerves and intestinal mast cells modulate responses to enterotoxins. News Physiol. Sci. 13:58-63.
41. Qiu, B., C. Pothoulakis, I. Castagliuolo, Z. Nikulasson, and J. T. LaMont. 1996. Nitric oxide inhibits rat intestinal secretion by Clostridium difficile toxin A but not Vibrio cholerae enterotoxin. Gastroenterology 111:409-418.
42. Ralevic, V., and G. Burnstock. 1998. Receptors for purines and pyrimidines. Pharmacol. Rev. 50:413-492.
43. Rehg, J. E. 1980. Cecal toxin(s) from guinea pigs with clindamycin-associated colitis, neutralized by Clostridium sordellii antitoxin. Infect. Immun. 27:387-390.
44. Safieh-Garabedian, B., S. Poole, A. Allchorne, J. Winter, and C. J. Woolf. 1995. Contribution of interleukin-1 beta to the inflammation-induced increase in nerve growth factor levels and inflammatory hyperalgesia. Br. J. Pharmacol. 115:1265-1275.
45. Salvatore, C. A., et al. 2000. Disruption of the A(3) adenosine receptor gene in mice and its effect on stimulated inflammatory cells. J. Biol. Chem. 275:4429-4434.
46. Sands, W. A., A. F. Martin, E. W. Strong, and T. M. Palmer. 2004. Specific inhibition of nuclear factor-kappaB-dependent inflammatory responses by cell type-specific mechanisms upon A2A adenosine receptor gene transfer. Mol. Pharmacol. 66:1147-1159.
47. Siegmund, B., et al. 2001. Adenosine kinase inhibitor GP515 improves experimental colitis in mice. J. Pharmacol. Exp. Ther. 296:99-105.
48. Sipka, S., et al. 2005. Adenosine inhibits the release of interleukin-1beta in activated human peripheral mononuclear cells. Cytokine 31:258-263. (Pubitemid 41097361)
49. Soares, A. C., et al. 2006. Dual function of the long pentraxin PTX3 in resistance against pulmonary infection with Klebsiella pneumoniae in transgenic mice. Microbes. Infect. 8:1321-1329.
50. Souza, D. G., et al. 2009. The long pentraxin PTX3 is crucial for tissue inflammation after intestinal ischemia and reperfusion in mice. Am. J. Pathol. 174:1309-1318.
51. Souza, D. G., et al. 2002. Increased mortality and inflammation in tumor necrosis factor-stimulated gene-14 transgenic mice after ischemia and reperfusion injury. Am. J. Pathol. 160:1755-1765.
52. Sullivan, G. W., J. M. Rieger, W. M. Scheld, T. L. Macdonald, and J. Linden. 2001. Cyclic AMP-dependent inhibition of human neutrophil oxidative activity by substituted 2-propynylcyclohexyl adenosine A(2A) receptor agonists. Br. J. Pharmacol. 132:1017-1026.
53. Van der Weyden, M. B., and W. N. Kelley. 1976. Human adenosine deaminase. Distribution and properties. J. Biol. Chem. 251:5448-5456.
54. Warny, M., et al. 2005. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366:1079-1084. (Pubitemid 41338761)
55. Wu, W. P., et al. 2002. Decreased inflammatory pain due to reduced carrageenan-induced inflammation in mice lacking adenosine A3 receptors. Neuroscience 114:523-527.
56. Xaus, J., et al. 1999. Adenosine inhibits macrophage colony-stimulating factor-dependent proliferation of macrophages through the induction of p27kip-1 expression. J. Immunol. 163:4140-4149. (Pubitemid 29474476)
57. Yang, D., et al. 2006. The A2B adenosine receptor protects against inflammation and excessive vascular adhesion. J. Clin. Investig. 116:1913-1923.